Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
KY 19382 is an inhibitor of the protein-protein interaction between CXXC-type zinc finger protein 5 (CF5) and Dishevelled (Dvl; IC50 = 19 nM).1 It is also an inhibitor of glycogen synthase kinase 3β (GSK3β; IC50 = 10 nM). KY 19382 (100 nM) increases expression of the mRNA encoding Wnt1-inducible signaling pathway protein 1 (WISP-1) and Axin2, markers of Wnt pathway activation, in ATDC-5 chondrogenic cells and increases nuclear and cytosolic levels of β-catenin in the same cells. KY 19382 (0.1 mg/kg per day) increases bone plate growth and tibia length in adolescent mice. It increases β-catenin levels in primary human dermal papilla cells, and topical application of KY 19382 promotes hair regrowth in normal and diabetic mice.2,3
WARNING This product is not for human or veterinary use.
1. CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth. Life Sci. Alliance 2(2), e201800254 (2019).
2. KY19382, a novel activator of Wnt/β-
3. Wnt/β-